Drug
Fluzoparib clinical trials
Also written SHR3162, HS10160 and Fuzuloparib.
- studies test it
- 79
- open now
- 36
- in phase 3
- 9
- first study started
- 2015
Keep track of what changes. Save the fluzoparib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
79 studies that test it; most in 2023 (14)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 8 |
| 2020 | 13 |
| 2021 | 10 |
| 2022 | 8 |
| 2023 | 14 |
| 2024 | 10 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 26
- Phase 2
- 49
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 31 · Other 48
Jiangsu HengRui Medicine Co., Ltd. (27) · Fudan University (12) · Sun Yat-sen University (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Atridia Pty Ltd. (3) · Qilu Hospital of Shandong University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Zhimin Shao (1)
Often tested with
Tested in the same studies.
Apatinib (16) · Camrelizumab (13) · Paclitaxel (9) · Bevacizumab (7) · Albumin-Bound Paclitaxel (5) · Dalpiciclib (5) · Adebrelimab (5) · Temozolomide (4)
Studies
Open first, then newest update. How each study uses fluzoparib is read from its arms, and is right about nine times in ten.
Testing it · 79
- Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast CancerNot yet recruitingPhase 2Harbin Medical UniversityNCT07752550Written as Retlirafusp alfa+Fluzoparib
- Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter StudyRecruitingPhase 2Peking University People's HospitalNCT05576389Written as Camrelizumab+Fluzoparib
- Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian CancerNot yet recruitingPhase 2Shandong UniversityNCT07647653Written as Fluzoparib+Bevacizumab
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Fluzoparib
- Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian CancerNot yet recruitingPhase 2Jinhua ZhouNCT07382713Written as Fluzoparib
- Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)Not yet recruitingPhase 2Fudan UniversityNCT07353437Written as Fluzoparib
- An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular TypingNot yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07141771Written as Fluzoparib
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06255392Written as Fluzoparib
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed GlioblastomaNot yet recruitingPhase 2Tongji HospitalNCT07047066Written as Fluzoparib with Temozolomide
- Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing SarcomaRecruitingPhase 2Sun Yat-sen UniversityNCT06827717Written as irinotecan liposome (II) + temozolomide + fluzoparib
- Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue SarcomaRecruitingPhase 2Fujun ZhangNCT05894018Written as Fluzoparib
- Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian CancerRecruitingPhase 2Qilu Hospital of Shandong UniversityNCT06735326Written as Fluzoparib
- Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian CancerRecruitingPhase 1/2Xing XieNCT04518501Written as Arsenic trioxide Tablet +Fuzuloparib Capsules
- Fluzoparib Neoadjuvant Therapy for Ovarian CancerRecruitingPhase 2Qilu Hospital of Shandong UniversityNCT06541314Written as Fluzoparib
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT05594095Written as Fluzoparib
- Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular SubtypingNot yet recruitingPhase 2Fudan UniversityNCT06561022Written as Fluzoparib
- Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian CancerNot yet recruitingPhase 2Fudan UniversityNCT06552858Written as Fluzoparib
- Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian CancerNot yet recruitingPhase 3Anhui Provincial HospitalNCT06539091Written as Fluzoparib
- Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian CancerNot yet recruitingPhase 2The First Hospital of Jilin UniversityNCT06446206Written as Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib
- Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial CancerRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06413992Written as Fluzoparib
See all 79 studies that test fluzoparib →
Given in every arm · 5 — fluzoparib is usual care beside what is tested
- A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian CancerNot yet recruitingPhase 2Qinglei GaoNCT07355010Written as fuzuloparib
- A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid TumorsRecruitingPhase 1/2Risen (Suzhou) Pharma Tech Co., Ltd.NCT06208410Written as Fluzoparib Capsules
- Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian CancerNot yet recruitingPhase 3The First Affiliated Hospital of Xiamen UniversityNCT06188455Written as Fluzoparib Capsules
- A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung CancerCompletedPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT04400188Written as Fluzoparib
- Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung CancerStatus unknownPhase 2Liu ZhenhuaNCT04933175Written as Fluzoparil
Codes
What other systems call fluzoparib · ClinicalTrials.gg INT001910
- MeSH (NLM) C000722917fluzoparibOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722917 | fluzoparib | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.